alexa Higher Trough Concentrations of Infliximab are Associated with Clinical Remission and Mucosal Healing in Patients with Inflammatory Bowel Disease | OMICS International| Abstract

ISSN: 2476-1958

Journal of Inflammatory Bowel Diseases & Disorders

  • Research Article   
  • J Inflam Bowel Dis & Disord 2016, Vol 1(1): 104
  • DOI: 10.4172/2476-1958.1000104

Higher Trough Concentrations of Infliximab are Associated with Clinical Remission and Mucosal Healing in Patients with Inflammatory Bowel Disease

Parra RS*, Marley Ribeiro Feitosa, José Joaquim Ribeiro Da Rocha and Omar Féres
Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Brazil
*Corresponding Author : Parra RS, Department of Surgery and Anatomy, Ribeirao Preto Medical School, University of São Paulo, (USP), 14048-900, Brazil, Tel: 55 (16) 36021000, 55 (16) 36022509, Email: [email protected]

Received Date: Mar 10, 2016 / Accepted Date: Mar 29, 2016 / Published Date: Apr 02, 2016

Abstract

Objective: Few studies have correlated the infliximab (IFX) trough concentration, clinical remission (CM) and mucosal healing (MH). The purpose of the study was to determine if higher IFX trough levels are associated with MH and CR, in a group of Brazilian inflammatory bowel disease patients. Methods: Cross-sectional study of 51 IBD patients in IFX maintenance therapy, at a medical center, in Brazil. IFX serum levels were obtained from blood samples collected immediately before drug infusion. The IFX trough levels were correlated with clinical and endoscopic scores and a univariate analysis was conducted to identify factors associated with CR and MH. Results: IFX trough concentration ≥ 2 μg/mL was associated with higher CR (84.2% vs. 28.1%; P<0.001) and MH (83.3% vs. 25.0%; P=0.001). Trough levels of 2.0 μg/mL were 89% specific for CR (sensibility=66%; P<0.001) and 89% specific for MH (sensibility =64%; P<0.001). On univariate analysis, IFX trough concentration was the only variable associated with CR and MH. Conclusion: The study found a significant association between IFX trough level ≥ 2 μg/mL, CR and MH. Therapeutic drug monitoring is an important tool in IBD patients and should routinely be performed to optimize treatment.

Keywords: Infliximab, Therapy, Monitoring, Biologic availability, Crohn disease, Ulcerative colitis, Remission induction

Citation: Parra RS, Feitosa MR, Da Rocha JJR, Féres O (2016) Higher Trough Concentrations of Infliximab are Associated with Clinical Remission and Mucosal Healing in Patients with Inflammatory Bowel Disease. J Inflam Bowel Dis & Disord 1: 104. Doi: 10.4172/2476-1958.1000104

Copyright: © 2016 Para RS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment
Share This Article
Relevant Topics
Article Usage
  • Total views: 8581
  • [From(publication date): 6-2016 - Apr 24, 2018]
  • Breakdown by view type
  • HTML page views: 8499
  • PDF downloads: 82